Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BETA Technologies, Inc.BETA · Entity 1930 | Director | June 11, 2026 | June 12, 2026 |
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | Director · Chairperson & CEO | October 13, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BETA Technologies, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 8,213 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 7,142 · Balance 8,213 |
UNITED THERAPEUTICS Corp
Report date October 13, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby Trust | 333,943 |
Reported balance
After 2026-10-13 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-10-13 · Exercise / conversion · Acquired 9,500 · Balance 333,943 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 333,304 |
Reported balance
After 2026-10-13 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-10-13 · Sale · Disposed 639 · Balance 333,304 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F3: This transaction was executed in multiple trades at prices ranging from $542.06 to $543.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 330,964 |
Reported balance
After 2026-10-13 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2026-10-13 · Sale · Disposed 2,340 · Balance 330,964 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F4: This transaction was executed in multiple trades at prices ranging from $543.06 to $544.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 329,472 |
Reported balance
After 2026-10-13 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2026-10-13 · Sale · Disposed 1,492 · Balance 329,472 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F5: This transaction was executed in multiple trades at prices ranging from $544.08 to $545.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 327,965 |
Reported balance
After 2026-10-13 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2026-10-13 · Sale · Disposed 1,507 · Balance 327,965 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F6: This transaction was executed in multiple trades at prices ranging from $545.08 to $546.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 326,513 |
Reported balance
After 2026-10-13 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2026-10-13 · Sale · Disposed 1,452 · Balance 326,513 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F7: This transaction was executed in multiple trades at prices ranging from $546.08 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 325,883 |
Reported balance
After 2026-10-13 transaction · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · 2026-10-13 · Sale · Disposed 630 · Balance 325,883 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F8: This transaction was executed in multiple trades at prices ranging from $547.08 to $547.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 325,185 |
Reported balance
After 2026-10-13 transaction · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · 2026-10-13 · Sale · Disposed 698 · Balance 325,185 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F9: This transaction was executed in multiple trades at prices ranging from $548.12 to $549.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,683 |
Reported balance
After 2026-10-13 transaction · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · 2026-10-13 · Sale · Disposed 502 · Balance 324,683 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F10: This transaction was executed in multiple trades at prices ranging from $549.25 to $550.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,523 |
Reported balance
After 2026-10-13 transaction · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · 2026-10-13 · Sale · Disposed 160 · Balance 324,523 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F11: This transaction was executed in multiple trades at prices ranging from $550.31 to $551.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,443 |
Reported balance
After 2026-10-13 transaction · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · 2026-10-13 · Sale · Disposed 80 · Balance 324,443 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F12: This transaction was executed in multiple trades at prices ranging from $551.37 to $551.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 249,108 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 249,108 F13: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 45,596 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 15
Holding and transaction disclosures are not merged.
1 source rowRow 15 · Balance 45,596 F14: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 8,902 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 16
Holding and transaction disclosures are not merged.
1 source rowRow 16 · Balance 8,902 F15: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.76 · Expires 2027-03-15 | Indirectby Trust | 242,910 |
Reported balance
After 2026-10-13 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-10-13 · Exercise / conversion · Disposed 9,500 · Balance 242,910 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F16: These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023. F17: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Direct | 40,513 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 40,513 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 166 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 166 |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
F10: This transaction was executed in multiple trades at prices ranging from $549.25 to $550.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11: This transaction was executed in multiple trades at prices ranging from $550.31 to $551.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F12: This transaction was executed in multiple trades at prices ranging from $551.37 to $551.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F13: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F14: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F15: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F16: These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.
F17: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F3: This transaction was executed in multiple trades at prices ranging from $542.06 to $543.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $543.06 to $544.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $544.08 to $545.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $545.08 to $546.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $546.08 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8: This transaction was executed in multiple trades at prices ranging from $547.08 to $547.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9: This transaction was executed in multiple trades at prices ranging from $548.12 to $549.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,164 | $352.57 | $410,387.52 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 18 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F15 · price: This transaction was executed in multiple trades at prices ranging from $351.97 to $352.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 459 | $351.47 | $161,323.08 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 17 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,365 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F14 · price: This transaction was executed in multiple trades at prices ranging from $350.93 to $351.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 390 | $350.10 | $136,537.75 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 16 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,824 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F13 · price: This transaction was executed in multiple trades at prices ranging from $349.43 to $350.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 339 | $348.76 | $118,229.33 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 15 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,214 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F12 · price: This transaction was executed in multiple trades at prices ranging from $348.28 to $349.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 837 | $347.91 | $291,202.43 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 14 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,553 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F11 · price: This transaction was executed in multiple trades at prices ranging from $347.23 to $348.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 340 | $346.34 | $117,754.65 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 13 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,390 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F10 · price: This transaction was executed in multiple trades at prices ranging from $346.07 to $346.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,600 | $129.49 | $466,164.00 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 12 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,600 | $0.00 Strike: $129.49 | $0.00 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · derivative · entry 25 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,669 Underlying: Common Stock · 3,600 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 73 | $353.17 | $25,781.41 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 11 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 173 | $351.81 | $60,863.67 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 10 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F9 · price: This transaction was executed in multiple trades at prices ranging from $351.49 to $352.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 237 | $350.61 | $83,094.93 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 9 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 376 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F8 · price: This transaction was executed in multiple trades at prices ranging from $350.49 to $350.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 151 | $349.47 | $52,769.80 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 613 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F7 · price: This transaction was executed in multiple trades at prices ranging from $349.00 to $349.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 660 | $348.22 | $229,827.71 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 764 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $347.90 to $348.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 640 | $347.48 | $222,384.06 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,424 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $346.80 to $347.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 220 | $345.66 | $76,045.24 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,064 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $345.25 to $345.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 138 | $343.64 | $47,422.32 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,284 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 362 | $343.10 | $124,202.06 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,422 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $342.59 to $343.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 946 | $341.76 | $323,306.76 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,784 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $341.28 to $342.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,600 | $129.49 | $466,164.00 |
DisclosureSEC source: 0001415889-24-022033 · form4-08222024_040801.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,600 | $0.00 Strike: $129.49 | $0.00 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · derivative · entry 23 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,669 Underlying: Common Stock · 3,600 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 48 | $350.33 | $16,815.65 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · nonDerivative · entry 17 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F13 · price: This transaction was executed in multiple trades at prices ranging from $350.01 to $350.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 808 | $348.86 | $281,881.06 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · nonDerivative · entry 16 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F12 · price: This transaction was executed in multiple trades at prices ranging from $348.71 to $349.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 639 | $348.23 | $222,516.93 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · nonDerivative · entry 15 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 986 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F11 · price: This transaction was executed in multiple trades at prices ranging from $347.70 to $348.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 413 | $346.89 | $143,264.45 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · nonDerivative · entry 14 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,625 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F10 · price: This transaction was executed in multiple trades at prices ranging from $346.48 to $347.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 219 | $345.74 | $75,717.21 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · nonDerivative · entry 13 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,038 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F9 · price: This transaction was executed in multiple trades at prices ranging from $345.25 to $345.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 127 | $344.70 | $43,777.38 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · nonDerivative · entry 12 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,257 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F8 · price: This transaction was executed in multiple trades at prices ranging from $344.23 to $344.78. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 205 | $343.79 | $70,477.52 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · nonDerivative · entry 11 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,384 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F7 · price: This transaction was executed in multiple trades at prices ranging from $343.10 to $344.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 41 | $341.31 | $13,993.67 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · nonDerivative · entry 10 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,589 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $341.25 to $341.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 152 | $339.93 | $51,669.79 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · nonDerivative · entry 9 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,630 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $339.76 to $340.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 256 | $339.35 | $86,873.98 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · nonDerivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,782 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $338.53 to $339.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 285 | $337.99 | $96,326.69 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,038 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $337.28 to $338.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 118 | $335.84 | $39,628.66 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,323 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $335.65 to $336.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 78 | $334.49 | $26,090.22 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,441 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 96 | $333.11 | $31,978.56 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,519 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 79 | $331.53 | $26,190.87 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,615 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 36 | $329.02 | $11,844.72 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,694 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,600 | $129.49 | $466,164.00 |
DisclosureSEC source: 0001415889-24-021817 · form4-08212024_040801.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,600 | $0.00 Strike: $129.49 | $0.00 |
DisclosureSEC source: 0001415889-24-021584 · form4-08192024_040822.xml · derivative · entry 20 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,269 Underlying: Common Stock · 3,600 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 157 | $323.06 | $50,720.33 |
DisclosureSEC source: 0001415889-24-021584 · form4-08192024_040822.xml · nonDerivative · entry 13 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F12 · price: This transaction was executed in multiple trades at prices ranging from $322.81 to $323.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 660 | $321.92 | $212,467.79 |
DisclosureSEC source: 0001415889-24-021584 · form4-08192024_040822.xml · nonDerivative · entry 12 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 287 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F11 · price: This transaction was executed in multiple trades at prices ranging from $321.58 to $322.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,734 | $320.97 | $556,561.11 |
DisclosureSEC source: 0001415889-24-021584 · form4-08192024_040822.xml · nonDerivative · entry 11 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 947 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F10 · price: This transaction was executed in multiple trades at prices ranging from $320.57 to $321.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 613 | $319.99 | $196,152.03 |
DisclosureSEC source: 0001415889-24-021584 · form4-08192024_040822.xml · nonDerivative · entry 10 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,681 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F9 · price: This transaction was executed in multiple trades at prices ranging from $319.44 to $320.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2 | $318.49 | $636.97 |
DisclosureSEC source: 0001415889-24-021584 · form4-08192024_040822.xml · nonDerivative · entry 9 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,294 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F8 · price: This transaction was executed in multiple trades at prices ranging from $318.38 to $318.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 434 | $317.73 | $137,893.78 |
DisclosureSEC source: 0001415889-24-021584 · form4-08192024_040822.xml · nonDerivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,296 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F7 · price: This transaction was executed in multiple trades at prices ranging from $317.38 to $318.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,600 | $129.49 | $466,164.00 |
DisclosureSEC source: 0001415889-24-021584 · form4-08192024_040822.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,600 | $0.00 Strike: $129.49 | $0.00 |
DisclosureSEC source: 0001415889-24-021584 · form4-08192024_040822.xml · derivative · entry 19 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,869 Underlying: Common Stock · 3,600 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 372 | $325.91 | $121,238.85 |
DisclosureSEC source: 0001415889-24-021584 · form4-08192024_040822.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $325.69 to $326.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 294 | $324.94 | $95,532.07 |
DisclosureSEC source: 0001415889-24-021584 · form4-08192024_040822.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 502 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $324.53 to $325.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,025 | $323.76 | $331,857.28 |
DisclosureSEC source: 0001415889-24-021584 · form4-08192024_040822.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 796 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $323.43 to $324.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,084 | $322.67 | $349,773.20 |
DisclosureSEC source: 0001415889-24-021584 · form4-08192024_040822.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,821 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $322.36 to $323.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.